NASDAQ:ALLO Allogene Therapeutics (ALLO) Stock Price, News & Analysis $1.50 -0.01 (-0.66%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.50 +0.00 (+0.33%) As of 07/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Allogene Therapeutics Stock (NASDAQ:ALLO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Allogene Therapeutics alerts:Sign Up Key Stats Today's Range$1.45▼$1.5450-Day Range$1.06▼$1.6652-Week Range$0.86▼$3.78Volume2.79 million shsAverage Volume3.53 million shsMarket Capitalization$328.10 millionP/E RatioN/ADividend YieldN/APrice Target$8.44Consensus RatingModerate Buy Company Overview Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Read More Allogene Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreALLO MarketRank™: Allogene Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 370th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingAllogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAllogene Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Allogene Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Allogene Therapeutics are expected to decrease in the coming year, from ($1.28) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Allogene Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.99% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Allogene Therapeutics has recently increased by 2.04%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.99% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Allogene Therapeutics has recently increased by 2.04%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News SentimentN/A News SentimentAllogene Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Allogene Therapeutics this week, compared to 4 articles on an average week.Search Interest7 people have searched for ALLO on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows6 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.20% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Allogene Therapeutics' insider trading history. Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Stock News HeadlinesBrokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Price Target at $8.44July 20, 2025 | americanbankingnews.comAllogene Therapeutics And 2 Other Promising Penny Stocks To WatchJuly 14, 2025 | finance.yahoo.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains. | Weiss Ratings (Ad)ALLO - Allogene Therapeutics Inc Ownership - MorningstarJuly 3, 2025 | morningstar.comMALLO - Allogene Therapeutics Inc Dividends - MorningstarJune 27, 2025 | morningstar.comMSystemic Lupus Erythematosus Pipeline Heats Up as 120+ Companies Advance Cutting-Edge Therapies | DelveInsightJune 18, 2025 | theglobeandmail.comAllogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell CarcinomaJune 2, 2025 | msn.comAllogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCOJune 1, 2025 | globenewswire.comSee More Headlines ALLO Stock Analysis - Frequently Asked Questions How have ALLO shares performed this year? Allogene Therapeutics' stock was trading at $2.13 on January 1st, 2025. Since then, ALLO stock has decreased by 29.6% and is now trading at $1.50. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) posted its earnings results on Tuesday, May, 13th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28). Read the conference call transcript. When did Allogene Therapeutics IPO? Allogene Therapeutics (ALLO) raised $272 million in an initial public offering on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO. Who are Allogene Therapeutics' major shareholders? Top institutional shareholders of Allogene Therapeutics include Kingstone Capital Partners Texas LLC (0.16%), Bourgeon Capital Management LLC (0.05%), Vanguard Personalized Indexing Management LLC (0.03%) and Vontobel Holding Ltd. (0.02%). Insiders that own company stock include David D Chang, Arie Belldegrun, Geoffrey M Parker, Earl Martin Douglas, Veer Bhavnagri, Rafael Amado, Zachary Roberts, Franz B Humer, Timothy L Moore, Owen N Witte, Benjamin Machinas Beneski, Annie Yoshiyama and Stephen Mayo. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allogene Therapeutics investors own include Waste Connections (WCN), American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/13/2025Today7/26/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALLO CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees310Year Founded2018Price Target and Rating Average Price Target for Allogene Therapeutics$8.44 High Price Target$14.00 Low Price Target$4.00 Potential Upside/Downside+463.0%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$257.59 million Net MarginsN/A Pretax Margin-1,168,850.00% Return on Equity-52.98% Return on Assets-41.28% Debt Debt-to-Equity RatioN/A Current Ratio9.71 Quick Ratio9.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.75Miscellaneous Outstanding Shares218,731,000Free Float189,859,000Market Cap$328.10 million OptionableOptionable Beta0.31 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ALLO) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.